No Data
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $43
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $25
Express News | Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Restructures Leadership Team
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
